Milliken Completes Acquisition of Encapsys

US chemical producer Milliken has completed the acquisition of compatriot Encapsys from the Cypress Performance Group (CPG), a holding company formed by Sherman Capital Holdings in the merger of Encapsys with IPS Corporation.

Milliken’s management said the acquisition brings a unique combination of innovation, science and technology to the South Carolina-headquartered company. Coupled with Milliken’s ability to scale, the deal is expected to “propel efforts to deliver sustainable innovations.”

Appleton, Wisconsin-based Encapsys is regarded as a leading player in microencapsulation technologies, which put a uniform polymeric shell around a core material at the micron level to create capsules. These are leveraged by companies to achieve more sustainable products by advancing responsible consumption and efficient delivery of active materials, as Milliken explained.

As Encapsys is integrated into Milliken, the companies said daily operations will continue without interruption, including relationships with existing suppliers and customers.

Author: Dede Williams, Freelance Journalist

Milliken has completed the acquisition of compatriot Encapsys from the Cypress...
Milliken has completed the acquisition of compatriot Encapsys from the Cypress Performance Group. The Wisconsin firm is a leading player in microencapsulation technologies, which put a uniform polymeric shell around a core material at the micron level to create capsules. © AVAVA/Shutterstock

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.